214045-86-0

Usage

Uses

Used in Pharmaceutical Industry:
1-CHLORO-6-FLUOROISOQUINOLINE is used as a building block for the synthesis of various organic compounds, particularly in the development of new pharmaceuticals. Its unique structure and properties contribute to the creation of innovative drug candidates with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 1-CHLORO-6-FLUOROISOQUINOLINE serves as a key intermediate in the production of agrochemicals, such as pesticides and herbicides. Its reactivity and potential biological activity allow for the development of effective and targeted agrochemical products.
Used as a Research Tool:
1-CHLORO-6-FLUOROISOQUINOLINE is utilized as a research tool for studying the reactivity and properties of heterocyclic compounds. Its unique structure provides insights into the behavior of similar compounds, aiding in the advancement of scientific understanding and the development of new methodologies in organic chemistry.

Upstream product

• 1008-86-2 6-fluoroisoquinoline 2-oxide 
• 214045-85-9 6-fluoro-1,2-dihydroisoquinolin-1-one 
• 1372215-44-5 4-fluoro-2-((trimethylsilyl)ethynyl)benzaldehyde oxime 
• 1075-11-2 6-fluoroisoquinoline 

Downstream Products

• 848841-45-2 (4-tert-butyl-phenyl)-(6-fluoro-isoquinolin-1-yl)-amine 
• 1372215-45-6 1-(4-tert-butylphenyl)-6-fluoroisoquinoline 
• 1372215-46-7 1-(3,5-dimethylphenyl)-6-fluoroisoquinoline 
• 608515-77-1 6-fluoro-1-methylisoquinoline 

Relevant academic research and scientific papers

Preparation method of formaldehyde-substituted aza-condensed ring compound

The invention provides a preparation method of a formaldehyde-substituted aza-condensed ring compound, comprising the following steps: by using an aza-condensed ring lactam compound as a starting material, carrying out halogenation reaction, methylation reaction and methyl oxidation reaction to obtain the formaldehyde-substituted aza-condensed ring compound. According to the preparation method ofthe formaldehyde-substituted aza-condensed ring compound, the whole synthesis route is good in step repeatability, mild in operation condition and high in safety, and large-scale production and industrial popularization are facilitated; post-treatment energy consumption is low, a large amount of toxic wastewater is not generated, no pollution is caused to the environment, the production safety level and the production cost are reduced, application of green and environment-friendly industrial production is facilitated, and wide application prospects are achieved.

Indolo[3,2-b]carbazole/benzimidazole hybrid bipolar host materials for highly efficient red, yellow, and green phosphorescent organic light emitting diodes

By incorporating electron-accepting benzimidazole and electron-donating indolo[3,2-b]carbazole into one molecule, two novel donor-acceptor bipolar host materials, TICCBI and TICNBI, have been synthesized. The photophysical and electrochemical properties of the hybrids can be tuned through the different linkages (C- or N-connectivity) between the electronic donor and acceptor components. The promising physical properties of these two new compounds made them suitable for use as hosts doped with various Ir or Os-based phosphors for realizing highly efficient phosphorescent organic light emitting diodes (PhOLEDs). PhOLEDs using TICCBI and TICNBI as hosts incorporated with Ir-based emitters such as green (PPy)2Ir(acac), yellow (Bt) 2Ir(acac), and two new red emitters (35dmPh-6Fiq)2Ir(acac) (i3) and (4tBuPh-6Fiq)2Ir(acac) (i6) accomplished high external quantum efficiencies ranging from 14 to 16.2%. Nevertheless, the red PhOLED device incorporating TICNBI doped with the red emitter osmium(ii) bis[3-(trifluoromethyl)-5-(4-tert-butylpyridyl)-1,2,4-triazolate] dimethylphenylphosphine [Os(bpftz)2(PPhMe2)2] achieved a maximum external quantum efficiency, current efficiency, and power efficiency of 22%, 28 cd A-1, and 22.1 lm W-1, respectively, with CIE coordinates of (0.65,0.35). The external quantum efficiency remained high (20%) as the brightness reached to 1000 cd m -2, suggesting balanced charge fluxes within the emitting layer, rendering devices with limited efficiency roll-off. The Royal Society of Chemistry 2012.

Isoquinoline, Quinazoline and Phthalazine Derivatives

Disclosed are compounds and pharmaceutically acceptable salts of Formula I wherein R0, R5, R6, R7, n, Q1-Q5, Y, and X1-X3 are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.

1,4-DISUBSTITUTED ISOQUINILONE DERIVATIVES AS RAF-KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES

This invention relates to compounds of formula (I) wherein the variable substituents are described herein. The compounds are useful for the treatment of conditions and diseases characterized by an aberrant MAP kinase signaling pathway, such as cancer.

HEPATITIS C VIRUS INHIBITORS

Hepatitis C virus inhibitors are disclosed having the general formula:(I) wherein R1, R2, R3, R', B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds toinhibit HCV are also disclosed.